Disease relevance of BD 1047

• Therefore, the present study investigated the effect of BD 1047 on DTG-evoked hypothermia [1].

Psychiatry related information on BD 1047

• The amnesia produced by the efficacious dose of (+)-SKF 10047 was reversed by the specific antagonist, BD 1047 [2].
• None of the tested drugs (SCH 23390, sulpiride, S 33084, WAY 100635, BD 1047 and progesterone) - alone or in combination with pramipexole and fluoxetine or sertraline - changed locomotor activity [3].

High impact information on BD 1047

• The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors [4].
• The injection of BD 1047 alone did not alter body temperature, suggesting that endogenous sigma systems do not play a tonic role in thermoregulation [1].
• Recently, N-[2-(3,4-dichlorophenyl) ethyl]-N-methyl-2-(dimethylamino) ethylamine (BD 1047) has been identified as a functional sigma antagonist in vivo because of its high selectivity for sigma sites and its ability to block DTG-induced dystonia and cocaine-evoked behaviors [1].
• The obtained results show that DTG, the sigma1/sigma2 receptor agonist, exerts a synergistic effect with memantine, an uncompetitive NMDA receptor antagonist, in the forced swimming test in rats, and that progesterone and BD 1047, the sigma1 receptor antagonists, counteract this effect [5].

Analytical, diagnostic and therapeutic context of BD 1047

• Effect of BD 1047, a sigma(1) receptor antagonist, in the animal models predictive of antipsychotic activity [6].

References